

# Luye Pharma Group Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/L39D743C188BEN.html

Date: May 2025 Pages: 50 Price: US\$ 499.00 (Single User License) ID: L39D743C188BEN

# Abstracts

Luye Pharma Group Ltd. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Luye Pharma Group Ltd. and its competitors. This provides our Clients with a clear understanding of Luye Pharma Group Ltd. position in the Pharmaceuticals and Biotechnology Industry.

The report contains detailed information about Luye Pharma Group Ltd. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Luye Pharma Group Ltd.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Luye Pharma Group Ltd. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and



company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Luye Pharma Group Ltd. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Luye Pharma Group Ltd. business.

#### About Luye Pharma Group Ltd.

Luye Pharma Group Ltd. engages in the research, development, production, distribution, and sale of pharmaceutical drugs and new formulations for chemical drugs. The company offers prescription and over-the-counter drugs, including oncology, cardiovascular, orthopedics, neurology, gastroenterology, hepatology, and gynecology drugs. Its products comprise Lipusu, which targets and inhibits rapidly growing cancer cells and is used to treat ovarian, breast, and non-small cell lung cancers; Tiandixin, an anti-tumor polysaccharide that affects host immune systems; CMNa, a nitroimidazole radio-sensitizer, which is used as an adjuvant to radiotherapy; Maitongna that is used to treat inflammation and swelling resulting from ailments, such as hydrocephalus, intracephalic hematoma, chronic venous insufficiency, burns, traumas, fractures, and wounds; and Lutingnuo, which is used to treat liver aliments, including acute alcoholic hepatitis, alcoholic hepatic fibrosis, and liver cirrhosis. The company's products also include Nuosen that is used to treat gastroenterological ailments, such as duodenum ulcers, gastric ulcers and acute pathologic of gastric mucosa, compound gastric ulcers, and acute haemorrhage of the upper digestive tract; Okai, which is used to treat inflammation caused by dropsy and haematoma; Olai, an antiinflammatory agent that is used to relieve pain caused by dropsy and haematoma, as well as symptomatic treatment of phlebitis; Sidinuo, which is used to relieve pain resulting from oesteoporosis, hypercalcaemia, and metastasis bone tumors; Ximingting that is used for



the relief of perimenopausal and menopausal symptoms; and Hypocol/Lipascor, a cholesterol balancing product. It has operations in the People's Republic of China, Korea, Malaysia, Norway, Pakistan, Singapore, and Vietnam. The company was formerly known as AsiaPharm Group Ltd. Luye Pharma Group Ltd. was founded in 1994 and is based in Singapore, Singapore.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



# Contents

### RESEARCH METHODOLOGY

DISCLAIMER

## 1. LUYE PHARMA GROUP LTD. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

#### 2. LUYE PHARMA GROUP LTD. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

#### 3. LUYE PHARMA GROUP LTD. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

#### 4. LUYE PHARMA GROUP LTD. FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

# 5. LUYE PHARMA GROUP LTD. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Luye Pharma Group Ltd. Direct Competitors
- 5.2. Comparison of Luye Pharma Group Ltd. and Direct Competitors Financial Ratios
- 5.3. Comparison of Luye Pharma Group Ltd. and Direct Competitors Stock Charts
- 5.4. Luye Pharma Group Ltd. Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
- 5.4.2. Luye Pharma Group Ltd. Industry Position Analysis

# 6. LUYE PHARMA GROUP LTD. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

# 7. LUYE PHARMA GROUP LTD. EXPERTS REVIEW<sup>1</sup>

- 7.1. Experts Consensus
- 7.2. Experts Revisions

# 8. LUYE PHARMA GROUP LTD. ENHANCED SWOT ANALYSIS<sup>2</sup>

# 9. SINGAPORE PESTEL ANALYSIS<sup>2</sup>

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors



# **10. LUYE PHARMA GROUP LTD. IFE, EFE, IE MATRICES**<sup>2</sup>

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## 11. LUYE PHARMA GROUP LTD. PORTER FIVE FORCES ANALYSIS<sup>2</sup>

# 12. LUYE PHARMA GROUP LTD. VRIO ANALYSIS<sup>2</sup>

#### **APPENDIX: RATIO DEFINITIONS**

#### LIST OF FIGURES

Luye Pharma Group Ltd. Annual Revenues in Comparison with Cost of Goods Sold and

Gross Profit Profit Margin Chart Operating Margin Chart Return on Equity (ROE) Chart Return on Assets (ROA) Chart Debt to Equity Chart Current Ratio Chart Luye Pharma Group Ltd. 1-year Stock Charts Luye Pharma Group Ltd. 5-year Stock Charts Luye Pharma Group Ltd. vs. Main Indexes 1-year Stock Chart Luye Pharma Group Ltd. vs. Direct Competitors 1-year Stock Charts Luye Pharma Group Ltd. Article Density Chart

1 – Data availability depends on company's security policy.

2 – These sections are available only when you purchase a report with appropriate additional types of analyses. The complete financial data is available for publicly traded companies.

Luye Pharma Group Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis



# **List Of Tables**

### LIST OF TABLES

Luye Pharma Group Ltd. Key Facts Profitability Management Effectiveness Income Statement Key Figures **Balance Sheet Key Figures Cash Flow Statement Key Figures Financial Performance Abbreviation Guide** Luye Pharma Group Ltd. Key Executives Luye Pharma Group Ltd. Major Shareholders Luye Pharma Group Ltd. History Luye Pharma Group Ltd. Products Revenues by Segment Revenues by Region Luye Pharma Group Ltd. Offices and Representations Luye Pharma Group Ltd. SWOT Analysis Yearly Income Statement Including Trends Income Statement Latest 4 Quarters Including Trends Yearly Balance Sheet Including Trends Balance Sheet Latest 4 Quarters Including Trends Yearly Cash Flow Including Trends Cash Flow Latest 4 Quarters Including Trends Luye Pharma Group Ltd. Profitability Ratios Margin Analysis Ratios Asset Turnover Ratios **Credit Ratios** Long-Term Solvency Ratios Financial Ratios Growth Over Prior Year Luye Pharma Group Ltd. Capital Market Snapshot Luye Pharma Group Ltd. Direct Competitors Key Facts **Direct Competitors Profitability Ratios Direct Competitors Margin Analysis Ratios Direct Competitors Asset Turnover Ratios Direct Competitors Credit Ratios Direct Competitors Long-Term Solvency Ratios** Pharmaceuticals and Biotechnology Industry Statistics



Luye Pharma Group Ltd. Industry Position Company vs. Industry Income Statement Analysis Company vs. Industry Balance Sheet Analysis Company vs. Industry Cash Flow Analysis Company vs. Industry Ratios Comparison Luye Pharma Group Ltd. Consensus Recommendations<sup>1</sup> Analyst Recommendation Summary<sup>1</sup> Price Target Summary<sup>1</sup> Experts Recommendation Trends<sup>1</sup> Revenue Estimates Analysis<sup>1</sup> Earnings Estimates Analysis<sup>1</sup> Historical Surprises<sup>1</sup> Revenue Estimates Trend<sup>1</sup> Earnings Estimates Trend<sup>1</sup> Earnings Estimates Trend<sup>1</sup> Revenue Revisions<sup>1</sup>



# **ANALYSIS FEATURES**

#### **SWOT Analysis**

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

#### **Enhanced SWOT Analysis**

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

#### **PESTEL Analysis**

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Luye Pharma Group Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis



Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

## IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

#### **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

#### **VRIO** Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources Financial

Physical

Technological

Organizational

Intangible resources Human

Innovation and Creativity



Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?



# I would like to order

Product name: Luye Pharma Group Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: https://marketpublishers.com/r/L39D743C188BEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/L39D743C188BEN.html</u>